Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q3 2025 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, Nov 13, 2025

  1. Slide 1: Presentation of Interim Report Q3

    Presentation of Interim Report Q3 ©2025 Surgical Science. | All rights reserved.

  2. Slide 2: CEO comments – Q3 2025

    CEO comments – Q3 2025  Q3 was a clear step in the right direction for Surgical Science. ▫ All-time high net sales of SEKm 264. Group revenue grew by 14%. Surgical Science revenue – 19% growth adjusted for FX. Rolling 12 months  Educational Products stabilized with 8% growth SEKm ▫ High customer d

  3. Slide 3: Q3: Progress in the right direction

    Q3: Progress in the right direction SEKm Q3:  Net sales up 14% to SEKm 263.6 (231.8). In local currencies up 19%. SEKm 18.8 from IU.  Educational Products up 8% (-6% excl IU). Regions: Europe (+46%), Asia (-5%), Americas (+9%).  Industry/OEM up 20%. License revenues up 1%, SEKm 65.5 (65.0). Sim s

  4. Slide 4: Revenue streams

    REVENUE STREAMS SEKm  License rev’s: 25 (28) percent of total revenues. Lumpy for new entrants, revenues from several customers. Intuitive sales affected by lower subscription renewals on older generations.  Simulator sales up 14%.  Continued strong development rev’s. Consists of both robotics’ p

  5. Slide 5: Costs and EBIT margin Q3 2025

    COSTS AND EBIT MARGIN Q3 2025 Costs/margin as a percentage of sales,  Gross margin 65% (69). Lower license revenues, excluding restructuring costs currency effects, lower direct sales within Edu and inclusion of IU had a negative effect. Operating margin 11% (20)  Sales: 21% (18) of sales. SEKm 2

  6. Slide 6: Organization

    ORGANIZATION No of employees at end of period: 328 (270) Men 238 (196) Women 90 (74) Israel 152 (139) Sweden 70 (61) Market presence >90 countries USA 54 (54) UK 33 (1) Other 19 (16) * Offices / Development sites * Other: Primarily Germany and China. ©2025 Surgical Science. | All rights reserved. 5

  7. Slide 7: Adjusted EBIT

    ADJUSTED EBIT* Q3:  Adjusted EBIT SEKm 32.8. Adjusted for restructuring costs SEKm 34.3 (51.8), margin 13% (22). YTD:  Adjusted EBIT SEKm 46.1. Adjusted for acquisition and restructuring costs SEKm 74.0 (123.4), margin 10% (20). *Excluding acquisition and restructuring costs related to IU in Q1 an

  8. Slide 8: Finance net and taxes

    FINANCE NET AND TAXES  Finance net for the quarter was SEKm 3.0 (8.4). Interest on bank balances, revaluation of internal loans and IFRS 16 effect.  Tax expense for the quarter was SEKm -9.7 (-10.0).  Net result for the quarter was SEKm 20.4 (43.0). ©2025 Surgical Science. | All rights reserved.

  9. Slide 9: Cash flow

    CASH FLOW  Cash flow from operating activities SEKm -4.4 (22.1). Change in working capital SEKm -44.6 (-32.5). Inventory decreased while A/R increased.  Cash flow from investing activities SEKm -10.9 (-12.5) mainly investments in development costs.  Cash flow from financing activities SEKm 4.0 (-

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com Tom Englund, CEO tom.englund@surgicalscience.com Anna Ahlberg, CFO anna.ahlberg@surgicalscience.com ©2025 Surgical Science. | All rights reserved.

Surgical Science Sweden — Q3 2025 Earnings Presentation on 6ix